

ABSTRACT

The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to viral specific T cells that express chimeric anti-tumor receptors. These bi-specific T cell clones are a source of effector cells that persist *in vivo* in response to stimulation with viral antigen, leading to long-term function after their transfer to patients with cancer and autoimmune diseases.

1954-417.utilityapn.wpd